[¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
Glioblastoma is an aggressive type of brain tumour. Treating it can be very difficult because the brain has a natural protective shield called the blood–brain barrier. While this barrier keeps out harmful toxins, it can also stop life-saving cancer medicines from reaching the tumour cells. This research study is testing a specialised scanning dye, known as [¹⁸F]MC225, alongside PET scans. Doctors want to see how this dye moves through three areas: the main tumour, the brain tissue right next to it, and healthy areas of the brain. This trial is an imaging study, meaning it does not treat or cure the tumour directly. Instead, it helps scientists understand how the blood–brain barrier functions in people with glioblastoma. By learning how substances cross into the tumour, researchers hope to design more effective treatments in the future. The study is open to adults aged 18 and over.
At a glance
What is this study about?
The brain is protected by a remarkable natural filter known as the blood–brain barrier. This barrier tightly controls what can pass from your bloodstream into your brain tissue, keeping out harmful bacteria and toxins. However, when a person has a brain tumour like a glioblastoma, this protective wall can cause problems because it also blocks many chemotherapy drugs and other treatments from reaching the cancer cells.
In this study, researchers are looking at how the blood–brain barrier behaves in people with glioblastoma. To do this, they use a new scanning dye called [¹⁸F]MC225. This substance is a 'radiotracer'—a safe, mildly radioactive liquid that lights up on a special camera called a PET scanner. By tracking where the dye goes, doctors can measure how well the blood–brain barrier is working in real time.
The research team will compare images from three distinct areas of the head: the central tumour, the tissue surrounding the tumour, and healthy brain tissue on the opposite side. They will also compare the PET results with detailed MRI scans and, where possible, small samples of tissue removed during routine tumour surgery.
While this study will not shrink the tumour, it provides vital clues about how medicines travel into brain cancer. Understanding these pathways is an essential step towards creating new, targeted therapies that can successfully get past the brain's defences.
Key takeaways
- Tests a new scanning dye called [¹⁸F]MC225 using PET and MRI scans.
- Aims to understand how the brain's protective barrier works in people with glioblastoma.
- Open to adults aged 18 and older diagnosed with a glioblastoma brain tumour.
- This is an imaging study, meaning it does not treat or cure the tumour directly.
- The information gained could help doctors design better brain cancer medicines in the future.
Who may be eligible?
This study is open to adults aged 18 and older who have been diagnosed with a glioblastoma, which is a type of brain tumour. Both men and women are eligible to take part.
To join, participants need to be well enough to attend hospital visits and lie still for imaging scans, including PET and MRI scans. Because this is an imaging trial, it is often coordinated alongside your planned hospital care or surgery.
Your clinical care team will check whether this study is safe and suitable for your specific health needs. People who have certain medical implants that prevent them from having MRI scans, or those who cannot receive the scanning dye, may not be able to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with a glioblastoma brain tumour.
- I am able to lie still in a scanner for PET and MRI imaging.
- I am comfortable receiving an injection of a specialised scanning dye.
- I do not have any metal implants that prevent me from having an MRI scan.
What does participation involve?
Taking part generally involves one or two hospital visits for specialised scans. During the study visit, a small tube (cannula) will be placed into a vein in your arm. The research team will inject a small amount of the [¹⁸F]MC225 scanning dye through the tube before performing the PET scan.
You will also have detailed MRI scans so researchers can look closely at the blood vessels around the tumour. You will need to lie still on a comfortable scanner bed while the pictures are taken. If you are already scheduled to have surgery to remove your tumour, the researchers may ask to study a small piece of leftover tissue that would normally be discarded after your operation. The study team will check in on you shortly after your scan to ensure you feel well, and your total participation time is typically brief.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
Will the study scan cure or shrink my tumour?
No. This is an imaging research study designed to take detailed pictures, not a treatment trial. It will not cure or shrink your tumour.
Is the radioactive dye dangerous?
The dye uses a very small, carefully controlled dose of radiation. It breaks down quickly and leaves your body naturally through your urine, making it safe for research use.
Will I have to undergo an extra surgery to take part?
No. Researchers will only look at tissue that is already being removed during your planned operation, using surplus material that would otherwise be discarded.
Does this trial interfere with my standard cancer treatments?
The study team will work closely with your cancer doctors to ensure the scans fit around your standard care and do not delay your usual treatments.
What happens if I change my mind about taking part?
You can leave the study at any point. Deciding to withdraw will never affect your standard NHS care or your relationship with your medical team.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.